Power Law company profile

Alamar Biosciences

Biotech & Life Sciences · Hayward, United States · Founded 2018 · IPO 2026 Unicorn

Improving human health by developing innovative immunoassays and engineering picomolar affinity antibodies

Valuation

$1.71B

Market cap · May/2026

Revenue

$74M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

5 investors on Alamar Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Qiming Venture Partners

Series B+ 4 investors entered at this stage

Morningside Venture Partners

Samsara BioCapital

Sherpa Venture Partners

Illumina Ventures

Global footprint

Where Alamar Biosciences has talent and traffic

Workforce by country

🇺🇸 United States · Hayward HQ

Book a demo for the full country breakdown

Web traffic by country

25K monthly visits
across markets

🇺🇸 United States64.8%

🇨🇦 Canada11.2%

🇮🇳 India7.2%

🇮🇹 Italy5.6%

🇯🇵 Japan4%

Top 5 markets shown

Market sentiment

What the market is saying about Alamar Biosciences

An AI-synthesized read of the highest-engagement posts about Alamar Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alamar Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles